On Monday shares of ADURO BIOTECH, INC. (NASDAQ:ADRO) closed at $30.13. Roth Capital reaffirmed their buy rating on shares of Aduro BioTech (NASDAQ:ADRO) in a research note issued to investors on Monday. The firm currently has a $70.00 price target on the stock.
On Monday shares of Triple-S Management Corporation (NYSE:GTS) closed at $23.68. Company’s sales growth for last 5 years was 3.20% and EPS growth for next 5 years is recorded as 7.85%. Triple-S Management Corp (NYSE:GTS), a provider of managed care and related products, on Monday announced the retirement of Ramon Ruiz-Comas, its President and Chief Executive Officer, effective January 1, 2016.
On last trading day Advance Auto Parts Inc. (NYSE:AAP) moved up 0.17% to close at $151.88. Its volatility for the week is 1.76% while volatility for the month is 1.93%. AAP’s sales growth for past 5 years was 12.70% and its EPS growth for past 5 years was 18.80%. Advance Auto Parts Inc. (NYSE:AAP) monthly performance is 1.39%. Advance Auto Parts, Inc. (NYSE:AAP), will report its first quarter results before market open on Thursday, May 21, 2015. The Company will detail its results on a conference call scheduled to begin at 10 a.m. Eastern Time on Thursday, May 21, 2015
Ever-Glory International Group, Inc. (NASDAQ:EVK) has 74.53% insider ownership while its institutional ownership stands at 0.60%. In last trading activity company’s stock closed at $5.59. On May 15, Ever-Glory International Group, Inc. (NASDAQ:EVK) reported its financial results for the first quarter ended March 31, 2015. Total sales for the quarter were $97.9 million, a decrease of 7.7% compared to $106.0 million in the first quarter of last year. This decrease was primarily attributable to a 2.9% decreased sales in retail business as well as a 15.6% decreased sales in wholesale business.
On last trading day Mirati Therapeutics, Inc. (NASDAQ:MRTX) moved down -0.07% to close at $28.30. Its volatility for the week is 6.18% while volatility for the month is 5.90%. MRTX’s EPS growth for past 5 years was 36.50%. Mirati Therapeutics, Inc. (NASDAQ:MRTX) monthly performance is 2.57%. On May 13, Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that the Company will provide an update on its investigational targeted tyrosine kinase inhibitor candidates, MGCD265 and MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat, at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 29-June 2, 2015. The updates on MGCD265 will be presented as part of the developmental therapeutics category. MGCD516 and mocetinostat will be presented as clinical trials in progress.